Ipilimumab

伊匹木单抗

Report date: 2026/05/02 20:00:18
First In Class

Base Information

Drug NameIpilimumab
Drug Alias Name艾匹利木单抗Ipilimumabum易普力姆玛易普利姆玛Yervoy +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsUveal melanomaBrain metastasesSkin Melanoma +[131] 
Global Approved IndicationsMesotheliomaMelanoma
Approved Indications in ChinaMesothelioma
Original Approved Country/TerritoryUnited States
Original Approved Date2011/03/25
Country/TerritoryCzechiaBelgiumCanada +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co Ltd +[11] 
Inactive CompaniesOhsu Knight Cancer InstituteViralytics LtdStanford University +[11] 
Active IndicationsSkin MelanomaPenile Squamous Cell CarcinomaNeuroendocrine Carcinoma of Lung +[79] 
Inactive IndicationsUveal melanomaBrain metastasesHormone-Resistant Prostate Neoplasms +[52] 

Other Information

ATC CodeL01XC11
Related LinksWikipediaDrugBankKEGG